Denan Zhang

Dr. Denan Zhang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
JYJingbo Yang
Jingbo Yang
DZDenan Zhang
Denan Zhang
YCYiyang Cai
Yiyang Cai
KYkexin yu
kexin yu
MLMingming Li
Mingming Li
Xiujie ChenXiujie Chen
Xiujie Chen
Identifying drug phenotypiceffects, including therapeutic effects and adverse drug reactions (ADRs), is an inseparable part for evaluating the potentiality of new drug candidates (NDCs). However, current computational methods for predicting phenotypiceffects of NDCs are mainly based on the overall structure of an NDC or a related target. These approaches often lead to inconsistencies between the structures and functions and limit the prediction space of NDCs. In this study, first, we constructed quantitative associations of substructure-domain, domain-ADR, and domain-ATC through supervised learnings. Then, based on these established associations, substructure-phenotype relationships were constructed which were utilized to quantifying drug-phenotype relationships. Thus, this approach could achieve high-throughput and effective evaluations of the druggability of NDCs by referring to the established substructure-phenotype relationships and structural information of NDCs without additional prior knowledge. In a word, this approach through establishing drug-substructure-phenotype relationships can achieve quantitative prediction of phenotypes for a given NDC or drug without any prior knowledge except its structure information. The way can directly obtain the relationships between substructure and phenotype of a compound, which is more convenient to analyze the phenotypic mechanism of drugs and accelerate the process of rational drug design.

30 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
QMQingkang Meng
Qingkang Meng
FWFeng Wu
Feng Wu
GLGuoqi Li
Guoqi Li
FXFei Xu
Fei Xu
LLLei Liu
Lei Liu
Xiujie ChenXiujie Chen
Xiujie Chen
At present, most patients with oral squamous cell carcinoma (OSCC) are in the middle or advanced stages at the time of diagnosis. Advanced OSCC patients have a poor prognosis after traditional therapy, and the complex heterogeneity of OSCC has been proven to be one of the main reasons. Single-cell sequencing technology provides a powerful tool for dissecting the heterogeneity of cancer. However, most of the current studies at the single-cell level are static, while the development of cancer is a dynamic process. Thus, understanding the development of cancer from a dynamic perspective and formulating corresponding therapeutic measures for achieving precise treatment are highly necessary, and this is also one of the main study directions in the field of oncology. In this study, we combined the static and dynamic analysis methods based on single-cell RNA-Seq data to comprehensively dissect the complex heterogeneity and evolutionary process of OSCC. Subsequently, for clinical practice, we revealed the association between cancer heterogeneity and the prognosis of patients. More importantly, we pioneered the concept of pseudo-time score of patients, and we quantified the levels of heterogeneity based on the dynamic development process to evaluate the relationship between the score and the survival status at the same stage, finding that it is closely related to the prognostic status. The pseudo-time score of patients could not only reflect the tumor status of patients but also be used as an indicator of the effects of drugs on the patients so that the medication strategy can be adjusted on time. Finally, we identified candidate drugs and proposed precision medication strategies to control the condition of OSCC in two respects: treatment and blocking.

5 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
HXHongbo Xie
Hongbo Xie
DZDiheng Zeng
Diheng Zeng
Xiujie ChenXiujie Chen
Xiujie Chen
DHDiwei Huo
Diwei Huo
LLLei Liu
Lei Liu
MHMing Hu
Ming Hu
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Hongbo Xie1, *, Diheng Zeng1, *, Xiujie Chen1, *, Diwei Huo2, *, Lei Liu1, Denan Zhang1, Qing Jin1, Kehui Ke1 and Ming Hu1 1Department of Pharmacogenomics, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, PR China 2The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, PR China *These authors contributed equally to this work Correspondence to: Xiujie Chen, email: chenxiujie@ems.hrbmu.edu.cn Denan Zhang, email: zhangdenan@ems.hrbmu.edu.cn Keywords: drug-induced liver injury, personalized medicine, homology-modeling, molecular simulation, risk population prediction Received: July 06, 2017 Accepted: September 20, 2017 Published: October 05, 2017 ABSTRACT Idiosyncratic adverse drug reactions are drug reactions that occur rarely and unpredictably among the population. These reactions often occur after a drug is marketed, which means that they are strongly related to the genotype of the population. The prediction of such adverse reactions is a major challenge because of the lack of appropriate test models during the drug development process. In this study, we chose withdrawn drugs because the reasons why they were withdrawn and from which countries or regions is easily obtained. We selected Dilevalol and its chiral drug (Labetalol) as the investigatory drugs, as they have been withdrawn from a European market (Britain) because of serious hepatotoxicity. First, we searched for and obtained the Dilevalol-induced- liver-injury related protein, multidrug resistance protein 1 (MDR1), from the Comparative Toxicogenomics Database (CTD). Then, we searched and extracted 477 non-synonymous single nucleotide polymorphisms (nsSNP) on MDR1 in the dbSNP database. Second, we used the VarMod tool to predict the functional changes of MDR1 induced by these nsSNPs, from which we extracted the nsSNPs that significantly change the functions of this protein. Third, we built the three-dimensional structures of those variant proteins and used AutoDock to perform a docking study, choosing the best model to determine the sites of nsSNPs. Finally, we used the data from the 1000 Genomes Project to verify the dominant population distribution of the risk SNP. We applied the same strategy to the post-marketing drug-induced liver injury drugs to further test the feasibility of our method.

1 January 2024 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
QMQingkang Meng
Qingkang Meng
YCYiyang Cai
Yiyang Cai
KZKun Zhou
Kun Zhou
FXFei Xu
Fei Xu
DHDiwei Huo
Diwei Huo
Xiujie ChenXiujie Chen
Xiujie Chen
The phenotypes of drug action, including therapeutic actions and adverse drug reactions (ADRs), are important indicators for evaluating the druggability of new drugs and repositioning the approved drugs. Here, we provide a user-friendly database, DAPredict (http://bio-bigdata.hrbmu.edu.cn/DAPredict), in which our novel original drug action phenotypes prediction algorithm (Yang,J., Zhang,D., Liu,L. et al. (2021) Computational drug repositioning based on the relationships between substructure-indication. Brief. Bioinformatics, 22, bbaa348) was embedded. Our algorithm integrates characteristics of chemical genomics and pharmacogenomics, breaking through the limitations that traditional drug development process based on phenotype cannot analyze the mechanism of drug action. Predicting phenotypes of drug action based on the local active structures of drugs and proteins can achieve more innovative drug discovery across drug categories and simultaneously evaluate drug efficacy and safety, rather than traditional one-by-one evaluation. DAPredict contains 305 981 predicted relationships between 1748 approved drugs and 454 ADRs, 83 117 predicted relationships between 1478 approved drugs and 178 Anatomical Therapeutic Chemicals (ATC). More importantly, DAPredict provides an online prediction tool, which researchers can use to predict the action phenotypic spectrum of more than 110 000 000 compounds (including about 168 000 natural products) and corresponding proteins to analyze their potential effect mechanisms. DAPredict can also help researchers obtain the phenotype-corresponding active structures for structural optimization of new drug candidates, making it easier to evaluate the druggability of new drug candidates and develop more innovative drugs across drug categories. Database URL: http://bio-bigdata.hrbmu.edu.cn/DAPredict/

14 July 2024 in Heliyon
Verified
Journal Article
Open access
YWYing Wang
Ying Wang
YSYangguang Su
Yangguang Su
KZKairui Zhao
Kairui Zhao
DHDiwei Huo
Diwei Huo
ZDZhenshun Du
Zhenshun Du
DZDenan Zhang
Denan Zhang
At the beginning of the "Disease X" outbreak, drug discovery and development are often challenged by insufficient and unbalanced data. To address this problem and maximize the information value of limited data, we propose a drug screening model, LGCNN, based on convolutional neural network (CNN), which enables rapid drug screening by integrating features of drug molecular structures and drug-target interactions at both local and global (LG) levels. Experimental results show that LGCNN exhibits better performance compared to other state-of-the-art classification methods under limited data. In addition, LGCNN was applied to anti-SARS-CoV-2 drug screening to realize therapeutic drug mining against COVID-19. LGCNN transcends the limitations of traditional models for predicting interactions between single drug targets and shows new advantages in predicting multi-target drug-target interactions. Notably, the cross-coronavirus generalizability of the model is also implied by the analysis of targets, drugs, and mechanisms in the prediction results. In conclusion, LGCNN provides new ideas and methods for rapid drug screening in emergency situations where data are scarce.

Verified
Journal Article
Open access
PDF file
ZFZhijin Fu
Zhijin Fu
YLYanjiao Li
Yanjiao Li
ZDZhenshun Du
Zhenshun Du
DZDenan Zhang
Denan Zhang
LLLei Liu
Lei Liu
HXHongbo Xie
Hongbo Xie
The prediction of drug response would significantly improve the treatment of lung cancer. Tumor heterogeneity and complex signal transduction pathways lead to varied treatment effects among patients, but traditional computational approaches struggle to model the nonlinear, high-dimensional relationship between genes and drug responses. In order to develop a Generative Adversarial Network (GAN)-based model that can predict drug-induced gene expression profiles from lung cancer cell lines, we developed GRIP-Lung (Generative Model of Response to Drug-Induced Perturbation in Lung Cancer). By making use of biologically informed embeddings of cell line identity as well as drug treatment conditions, this model is able to gain a fairly good understanding of cell types and their transcriptional perturbations induced by different drugs. The GRIP-Lung model displayed reasonably good prediction ability in terms of predictive accuracy and showed high concordance between the predicted and experimental expression profiles. We not only predicted transcriptional changes induced by drug therapy but also used single-sample Gene Set Enrichment Analysis (ssGSEA) to classify post-treatment response states based on characteristic molecular biomarkers, offering a means for selecting effective drugs to target specific heterogeneity within lung tumors. The proposed GRIP-Lung framework faithfully reproduces drug-induced transcriptional perturbations in lung cell line models. By integrating biologically informed embeddings and adversarial learning, the model advances drug response prediction. This makes it a flexible computational tool for drug repositioning.